Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADOPT-lung
NCT06284317Phase 3Recruiting
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Jan 2025
- Primary completion
- Oct 2029
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 10
01
Overview
A Phase 3 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Started Jan 2025; status: recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06284317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06284317.